<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946500</url>
  </required_header>
  <id_info>
    <org_study_id>CISTA - 29BRC21.0123</org_study_id>
    <nct_id>NCT04946500</nct_id>
  </id_info>
  <brief_title>Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)</brief_title>
  <acronym>CISTA</acronym>
  <official_title>Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint&#xD;
      infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as&#xD;
      dual therapy in this indication, and provides many advantages. We conducted a multicenter&#xD;
      retrospective observational study evaluating the efficacy and safety of Clindamycin in&#xD;
      prosthetic joint infections due to staphylococcus between January 2013 and December 2019.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Failure of Clindamycine</measure>
    <time_frame>within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)</time_frame>
    <description>New diagnosis of PJI at the same site, caused by the same microbial agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Clindamycin</measure>
    <time_frame>During the treatment and 6 month after</time_frame>
    <description>Safety of Clindamycin in the treatment of PJI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between failure of Clindamycin and blood level of Clindamycin</measure>
    <time_frame>within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <condition>Staphylococcus</condition>
  <arm_group>
    <arm_group_label>Clindamycin and Rifampicin</arm_group_label>
    <description>Patients treated with Clindamycin and Rifampicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin and Fluoroquinolone</arm_group_label>
    <description>Patients treated with Clindamycin and Fluoroquinolone</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Prosthetic Joint Infections caused by Staphylococccus treated with&#xD;
        Clindamycin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with PJI defined according to the IDSA.&#xD;
&#xD;
          -  Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive&#xD;
             to Clindamycin.&#xD;
&#xD;
          -  Infection may be acute or chronic, nosocomial or community-acquired.&#xD;
&#xD;
          -  Patient having received a curative treatment with Clindamycin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic&#xD;
             foot infections, spondylodiscitis, infections in external fixator, surgical site&#xD;
             infections following neurosurgical management, bedsores, skin and soft tissue&#xD;
             infections.&#xD;
&#xD;
          -  Patients with mono-microbial infections other than Staphylococcus, multi-microbial&#xD;
             infections including other bacteria than Staphylococcus, suspected Osteoarticular&#xD;
             Infection without microbial identification.&#xD;
&#xD;
          -  Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype.&#xD;
&#xD;
          -  Patients having received suspensive treatment with Clindamycin.&#xD;
&#xD;
          -  Patients treated with Clindamycin as last line of treatment for a duration of less&#xD;
             than 14 days.&#xD;
&#xD;
          -  Patients refusing to participate&#xD;
&#xD;
          -  Patients under legal protection (guardianship, curatorship, ..)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three month and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

